Hyperfractionated Radiotherapy Alone Or In Sequential Combination Chemotherapy In Patients With Advanced Nasopharynx Cancer With Contraindications To Concurrent Radio-Chemotherapy - Long Term Results

The standard treatment of patients (pts) with advanced nasopharyngeal cancer (NPC) is conventional fractionated radiotherapy (CFRT) combined with concurrent platinum based chemotherapy (CHT). Induction CHT followed by CFRT or CFRT followed by adjuvant CHT may be effective in selected NPC pts, especially with low differentiated and/or bulky tumors. Our experiences with comorbidity touched HNC pts have recognised concurrent radio-chemotherapy as a too toxic for them and suggested that radiotherapy (RT) alone or RT combined with sequential CHT should be considered. In order to avoid the loss of chemoradiation enhancement of tumor responsiveness hyperfractionated RT (HpfxRT) is dedicated for such a pts allowing radiation dose escalation in the same time as for CFRT. The objective of this presentation is to report survival outcomes and treatment toxicity in pts with advanced NPC treated with HpfxRT alone or combined with induction or/and adjuvant CHT.